PDL BioPharma Value Stock - Dividend - Research Selection
Market price: 2,47 USD
PDL BioPharma Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||-32.443.000|
|Free cash flow||-34.906.000|
|Liabilities & Shareholders equity||716.119.000|
|Diluted shares outstanding||118.631.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||293.018.560,00 USD|
|Raw Data Source||US GAAP in Millionen USD|
|Stock Split||2001-10-10,2.0000/1.0000; 2000-08-23,2.0000/1.0000|
Description of the company
PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014. It has entered into licensing agreements with numerous entities that are independently developing or have developed humanized antibodies under which it has licensed certain rights under its Queen et al. patents to make, use, sell, offer for sale and import humanized antibodies.